Nova Scotia Pharmacare

COVID-19 Update : Nova Scotia Drugs and Therapeutics Committee Receipt and Review of Submissions

Due to the COVID 19 pandemic we have temporarily changed our process for the receipt and review of submissions. Until otherwise specified, requests to submit a product for review should be addressed to: ns.interchangeability.committee@medavie.bluecross.ca with the subject line “REQUEST to SUBMIT”.

The correspondence should include ONLY the product name and DIN as well as the submission type ( e.g., full, expedited, notice of change). Electronic submissions will not be accepted at this email address. Manufacturers will be notified via email of receipt of the submission request and the details on how to submit. We appreciate your understanding and patience.

Nova Scotia Drugs and Therapeutics Committee

The Nova Scotia Drugs and Therapeutics Committee, representing the professions of Medicine, Dentistry, and Pharmacy, is responsible for determining interchangeability among pharmaceutical products and for recommending to the Department of Health and Wellness those products which will appear as interchangeable in the Nova Scotia Formulary.

Pharmaceutical products are considered for interchangeability only when they are the subject of a formal submission which complies with the Nova Scotia Criteria for Interchangeability. This document includes the guidelines for interchangeability, a description of the review process, and the requirements for formal submissions with both submission forms and letter templates.

Meeting Dates
The next regular meeting of the Drugs and Therapeutics Committee is scheduled for:

9 June 2021.

Please note:

• All submissions requiring Committee review must be received no later than 4 weeks before the proposed meeting date.

• Meeting dates may change without notice and ad hoc meetings may be called without notice at the sole discretion of the Department of Health and Wellness.